Logo

American Heart Association

  2
  0


Final ID: MDP1665

Characterization of Isolated Right Ventricular Congestion in Cardiogenic Shock

Abstract Body (Do not enter title and authors here): Introduction: Right ventricular (RV) congestion has been associated with poor outcomes in cardiogenic shock (CS); however, the clinical profile of pts with CS & isolated RV congestion has been less well characterized. We aimed to describe the severity of illness, resource utilization & mortality in pts with isolated RV congestion compared to other congestive profiles.
Methods: The Critical Care Cardiology Trials Network is a multicenter registry of CICUs coordinated by the TIMI Study Group (Boston, MA). Pts with CS with invasive hemodynamic assessment within 24h of CICU admission (2018-2023) & not on mechanical circulatory support (MCS) at the time were included. Congestive profiles were defined by right atrial pressure (RAP) & pulmonary capillary wedge pressure (PCWP): isolated RV (RAP≥12 & PCWP<18); isolated left ventricular (LV: RAP<12 & PCWP≥18); biventricular (BiV: RAP≥12 & PCWP≥18), and non-congested (NC: RAP<12 & PCWP<18).

Results: Of 2121 pts with CS, 1186 (56%) met the inclusion criteria with 7.1% classified as RV congestion, 61.6% as BiV, 18.5% as LV & 12.7% as NC. The RV group was more likely to be female & have pulmonary disease than others & less likely to have prior HF or severe valve disease than LV & BiV. The RV congestion group had lower pulmonary artery pulsatility index & higher pulmonary vascular resistance than LV & NC (p<0.05 for all); MAP & CI were similar across groups. PE was a contributor to CS in 1.2% and pHTN in 13.1% of RV cases. The RV group more often presented with de novo HF-CS, where BiV & LV more often had acute on chronic HF-CS. The RV group tended to have worse shock severity by SOFA score, lactate, vasoactive-inotropic score (global p<0.05 for all) & SCAI stage (panel A) and was more likely to have a cardiac arrest (p=0.010). The RV group had greater use of mechanical ventilation & renal replacement, but lower use of MCS (panel B). CICU mortality was significantly higher in the RV group compared to other profiles (panel C), including after adjustment for cardiac arrest & CS etiology.
Conclusion: In pts with CS, isolated RV congestion was associated with the highest presenting illness severity, resource utilization & mortality when compared to other congestive profiles.
  • Kaur, Gurleen  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Berg, David  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Van Diepen, Sean  ( UNIVERSITY OF ALBERTA , Edmonton , Alberta , Canada )
  • Katz, Jason  ( NYU Langone , New York , New York , United States )
  • Guo, Jianping  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Morrow, David  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Bohula, Erin  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Gurleen Kaur: DO NOT have relevant financial relationships | David Berg: DO NOT have relevant financial relationships | Sean Van Diepen: DO NOT have relevant financial relationships | Jason Katz: DO have relevant financial relationships ; Researcher:Abbott Corporation:Active (exists now) ; Other (please indicate in the box next to the company name):Abiomed, DSMB Member:Active (exists now) ; Speaker:Zoll Corporation:Past (completed) | Jianping Guo: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):I am a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women’s Hospital from: : Abbott, Abiomed, Inc., Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Inc., Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc., Zora Biosciences:Active (exists now) | David Morrow: No Answer | Erin Bohula: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Fortune Teller Will See You Now... Prognostication in the CICU

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
Comparison of Right Ventricular Dysfunction Following Catheter-Directed, Half-Dose, and Full-Dose Thrombolysis for Acute Pulmonary Embolism

Koura Simran, Shah Parth, Sutherland David, Kumar Amudha, Wroblewski Igor, Darki Amir, Mallery Quinn, Clarke Jacob, Greathouse Frances, Choi Myoung Hyun, Riya Fnu, Bruno Elizabeth, Arora Punit, Malas Waddah

Ability of Composite Magnetic Resonance Brain Imaging Scores to Predict Functional Outcomes in Survivors of Cardiac Arrest

Nguyen Thuhien, Town James, Wahlster Sarah, Johnson Nicholas, Poilvert Nicolas, Lin Victor, Ukatu Hope, Matin Nassim, Davis Arielle, Taylor Breana, Thomas Penelope, Sharma Monisha

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available